Literature DB >> 15563926

Development of an antibody-detection ELISA for Fasciola hepatica and its evaluation against a commercially available test.

M R Salimi-Bejestani1, J W McGarry, S Felstead, P Ortiz, A Akca, D J L Williams.   

Abstract

An ELISA was developed for the detection of Fasciola hepatica antibody in serum of cattle. The assay was applied to sera from 258 naturally infected cattle, 256 non-infected cattle and six calves experimentally infected with F. hepatica. The diagnostic sensitivity and specificity of the ELISA test was 98% (95% confidence intervals, 96-100%) and 96% (95% confidence intervals, 93-98%) respectively at a cut-off value of 15% positivity. The results using sera from the experimentally infected calves showed that antibodies were first detected 2-4 weeks after infection. The ELISA test was also compared to the commercially available Bio-X bovine F. hepatica ELISA kit. A subset of 39 positive sera and 47 negative sera were selected from the samples used to evaluate the in-house test. The results indicated that the agreement between the two tests was almost perfect (k statistic=0.82).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15563926     DOI: 10.1016/j.rvsc.2004.08.005

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  35 in total

1.  [Multiple liver lesions accompanied by eosinophilia - a case report of fascioliosis].

Authors:  Eva Trifina; Johannes Spenger; Shahin Zandieh; Jörg Haller; Herbert Auer; Christian Osterreicher; Klaus Klaushofer; Peter Mikosch
Journal:  Wien Med Wochenschr       Date:  2011-09

2.  Ultrasonographic findings in cattle and buffaloes with chronic hepatic fascioliosis.

Authors:  Mohamed Tharwat
Journal:  Trop Anim Health Prod       Date:  2012-02-24       Impact factor: 1.559

3.  Development of two antibody detection enzyme-linked immunosorbent assays for serodiagnosis of human chronic fascioliasis.

Authors:  Kimberly Cabán-Hernández; José F Gaudier; Caleb Ruiz-Jiménez; Ana M Espino
Journal:  J Clin Microbiol       Date:  2013-12-18       Impact factor: 5.948

4.  Fasciola hepatica saposin-like protein-2-based ELISA for the serodiagnosis of chronic human fascioliasis.

Authors:  Olgary Figueroa-Santiago; Bonnibel Delgado; Ana M Espino
Journal:  Diagn Microbiol Infect Dis       Date:  2011-07       Impact factor: 2.803

5.  Prevalence of Fasciola hepatica (ELISA and fecal analysis) in ruminants from a semi-desert area in the northwest of Mexico.

Authors:  J A Munguía-Xóchihua; F Ibarra-Velarde; A Ducoing-Watty; N Montenegro-Cristino; H Quiroz-Romero
Journal:  Parasitol Res       Date:  2007-01-30       Impact factor: 2.289

6.  Fasciola hepatica and Schistosoma mansoni: identification of common proteins by comparative proteomic analysis.

Authors:  Nawal M Boukli; Bonnibel Delgado; Martha Ricaurte; Ana M Espino
Journal:  J Parasitol       Date:  2011-03-11       Impact factor: 1.276

7.  Leucine aminopeptidase is an immunodominant antigen of Fasciola hepatica excretory and secretory products in human infections.

Authors:  A Marcilla; J E De la Rubia; J Sotillo; D Bernal; C Carmona; Z Villavicencio; D Acosta; J Tort; F J Bornay; J G Esteban; R Toledo
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

Review 8.  Recent Developments in Recombinant Proteins for Diagnosis of Human Fascioliasis.

Authors:  Abolfazl Mirzadeh; Farid Jafarihaghighi; Elham Kazemirad; Shokouh Shahrokhi Sabzevar; Mohammad Hossein Tanipour; Mehdi Ardjmand
Journal:  Acta Parasitol       Date:  2020-09-24       Impact factor: 1.440

9.  Seasonal pattern of Fasciola hepatica antibodies in dairy herds in Northern Germany.

Authors:  Birte Kuerpick; Thomas Schnieder; Christina Strube
Journal:  Parasitol Res       Date:  2012-05-08       Impact factor: 2.289

10.  First Report of Human Fascioliasis in an Endemic Region of Bovine Fascioliasis in Caldas-Colombia.

Authors:  Jorge Enrique Perez-C; Etna Julieth Giraldo-Pinzon; Sandra Aguilar-Marín
Journal:  Vector Borne Zoonotic Dis       Date:  2016-04-05       Impact factor: 2.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.